Clinical Trial Update: Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC) [Phase 1]

View source ↗

Summary

This clinical trial update provides long-term follow-up results for sickle cell disease patients treated with genome-edited autologous hematopoietic stem and pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Genome-edited autologous hematopoietic stem and progenitor cells (HSPCs)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sickle Cell Disease | Phase 1 | Status: ACTIVE_NOT_RECRUITING